Geographic atrophy (GA) is the late manifestation of non-neovascular age-related macular degeneration (AMD) characterised by progressive loss of retinal pigment epithelium (RPE) and photoreceptors. Until now, it was a slowly progressive untreatable disease that led to vision loss.
Researchers in Norway have found that repeated intravitreal injections (IVI) with anti-vascular endothelial growth factor (anti-VEGF) improved some dry-eye disease symptoms in patients with neovascular age-related macular degeneration (nAMD).
Wellington Hospital paediatric optometrist Natalie Beardsworth has developed a child-friendly reading chart, filling a gap in optometrists’ vision-testing toolkit for children.
The Cornea and Contact Lens Society’s (CCLS’s) popular one-day conference, on Sunday 26 March, promises an exciting day of anterior-eye education and networking.
A US study found low blood sugar in diabetic retinopathy (DR) patients triggered an increase in production of vascular endothelial growth factor (VEGF) and angiopoietin-like 4 (ANGPTL4), exacerbating
UK-based Oxular Limited announced the US Food and Drug Administration has accepted its Investigational New Drug (IND) application for suprachoroidal OXU-001 for the treatment of diabetic macular
Apellis’ Syfovre (pegcetacoplan injection) has become the first US Food and Drug Administration (FDA) -approved treatment for geographic atrophy (GA) secondary to age-related macular degeneration
Focusing on ophthalmology and endoscopy, a new private surgical centre, Kāpiti Day Hospital, is set to open its doors in June.
The University of Auckland (UoA) is collaborating with Fred Hollows Foundation New Zealand to undertake a new and ambitious Pacific-focused research programme.
Planning is well underway for the 54th Royal Australian and New Zealand College of Ophthalmologist’s (RANZCO’s) annual scientific congress, ‘Reconnecting vision’, scheduled for 20-23 October at the Perth Convention and Exhibition Centre.
Researchers in China have identified a small molecule which restores visual function following optic nerve damage.
Archway randomised phase 3 trial of ranibizumab port delivery system for nAMDHolekamp N et alOphthalmology, 2022. 129(3): p. 295-307
